SUPERNUS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.96 USD | -3.47% |
|
-6.07% | +0.07% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 604M | Sales 2025 * | 627M | Capitalization | 1.59B |
|---|---|---|---|---|---|
| Net income 2024 * | 14M | Net income 2025 * | -41M | EV / Sales 2024 * | 2.64 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.54 x |
| P/E ratio 2024 * |
116
x | P/E ratio 2025 * |
-39.1
x | Employees | 652 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.98% |
More Fundamentals
* Assessed data
More news
Latest transcript on Supernus Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | -3.47% | ||
| 1 week | -6.07% | ||
| Current month | -3.79% | ||
| 1 month | -9.50% | ||
| 3 months | +3.76% | ||
| 6 months | +8.67% | ||
| Current year | +0.07% |
1 week
28.27
32.87
1 month
28.2732.87
Current year
26.2735.44
1 year
21.9935.96
3 years
21.9942.09
5 years
13.1242.09
10 years
7.0961.25
| Managers | Title | Age | Since |
|---|---|---|---|
Jack Khattar
FOU | Founder | 62 | 05-03-29 |
Timothy Dec
DFI | Director of Finance/CFO | 66 | 21-08-22 |
Frank Mottola
CTO | Chief Tech/Sci/R&D Officer | 52 | 04-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Georges Gemayel
BRD | Director/Board Member | 64 | 15-03-22 |
Charles Newhall
CHM | Chairman | 79 | 05-03-29 |
John Siebert
BRD | Director/Board Member | 84 | 10-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.94% | 0 M€ | -1.57% | ||
| 0.94% | 0 M€ | -4.02% | ||
| 0.38% | 0 M€ | -2.98% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 28.96 | -3.47% | 922,410 |
| 24-05-09 | 30 | -4.15% | 1,066,039 |
| 24-05-08 | 31.3 | +0.48% | 461,434 |
| 24-05-07 | 31.15 | +2.40% | 471,705 |
| 24-05-06 | 30.42 | -1.33% | 335,111 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâs Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
Sector
Pharmaceuticals
Calendar
2024-05-23
- R&D Day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
28.96
USD
Average target price
40.67
USD
Spread / Average Target
+40.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.07% | 1.59B | |
| +7.91% | 72.81B | |
| +12.64% | 9.13B | |
| -10.56% | 5.13B | |
| +58.79% | 4.99B | |
| +4.07% | 3.9B | |
| -16.90% | 2.48B | |
| -26.13% | 2.32B | |
| +19.31% | 2.17B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- SUPN Stock